Background The omega-3 polyunsaturated fatty acids derived from fish oils have been shown to modulate many factors believed to affect the pathogenesis of atherosclerosis. Because certain features of restenosis following angioplasty mimic some of the early changes of atherogenesis, some researchers have suggested that fish oil might prevent restenosis following angioplasty. We report the effects of omega-3 fatty acids on the rate of restenosis following percutaneous intraluminal coronary angioplasty (PTCA).
Methods and Results From August 1989 through September 1992, 551 patients were randomized to start receiving a daily dietary supplement of ten 1.0-g capsules containing 80 .6% ethyl esters of omega-3 fatty acids providing 4.1 g eicosapentaenoic acid (EPA) and 2.8 g docosahexaenoic acid (DHA) for 6 months or an equal amount of an ethyl ester of corn oil. Four hundred seventy subjects who were well matched for risk factors completed successful angioplasty of one or multiple lesions in native coronary vessels and constituted the study cohort, of whom 447 were evaluable at 6 months after PTCA. The criteria for restenosis were that the quantitative coronary S everal epidemiological studies -4 have suggested that there is an inverse relation between mortality from coronary heart disease and the dietary intake of omega-3 fatty acids derived from marine vertebrates. There also is considerable evidence that dietary fish oil supplements may reduce experimental atherosclerosis in some animals. 5 8 Laboratory studies have demonstrated that the ingestion of omega-3 fatty acids reduces the production in vivo of several factors believed to be atherogenic and increases the production of some antiatherogenic substances (reviewed in Reference 9).
angiography at 6 months show a >30% increase in narrowing at the stenosis site or loss of at least half of the gain achieved at the time of PTCA and final restenosis with <50% luminal diameter remaining. In 93% of the patients, the end point was determined by angiography and in all except 1% of these by quantitative coronary angiography. Compliance with the fish oil supplement was good as judged by incorporation of EPA and DHA in plasma and red blood cell phospholipids. The restenosis rate among analyzable patients was 46% for corn oil and 52% for fish oil (P=.37). The addition of 200 mg a-tocopherol for all subjects during the study had no effect on restenosis rates.
Conclusions This was the largest of such trials to date, and a supplement of 8 g/d of omega-3 fatty acids failed to prevent the usual high rate of restenosis after PTCA. No adverse effects were attributable to this large daily supplement of omega-3 fatty acids. (Circulation. 1994;90:2248-2257.)
Key Words: * restenosis * angioplasty * fish oil a fatty acids Because some features of the pathology, particularly the prompt proliferative response of arterial smooth muscle cells at the site of percutaneous transluminal coronary balloon angioplasty (PTCA), mimic features that characterize stages of atherosclerosis, it was suggested that ingestion of fish oils might prevent the high restenosis rate associated with angioplasty. Also, there appeared to be clear advantages to testing the effects of the fish oils on restenosis after PTCA: (1) The time necessary for such a study is relatively short since more than 80% of procedures that restenose will do so within 6 months of the procedure.10 (2) The restenosis rate is high, -50% when quantitative coronary angiography (QCA) is done by 6 months,1' despite present treatments. (3) Objective end points can be achieved with exit angiography. (4) There are more than 250 000 coronary angioplasty procedures performed annually in the United States,12 so significant prevention of restenosis by fish oil would be highly cost effective for this expensive procedure.
There have been nine reported clinical restenosis studies with fish oil supplements.13-21 These have achieved mixed results. One meta-analysis,22 which analyzed data from the first seven studies, concluded that although the combined data were "compatible with a small to moderate benefit of fish oil on restenosis, these results require confirmation in a randomized clinical trial large enough to distinguish reliably between a clinically meaningful benefit and a null result." The numbers of subjects in individual studies were too small, the procedures varied considerably among the studies, the dose and form of omega-3 supplement varied as did the time of supplement commencement in relation to PTCA, and end points for restenosis were not always rigorous. A second meta-analysis reported the following year was less critical of the evidence. 23 We report the results of a prospective, randomized, placebo-controlled, double-blind clinical trial designed to test the hypothesis that a dietary supplement of fish oil, given daily from 12 to 14 days before through 6 months after angioplasty, will reduce the frequency of restenosis.
Methods
From August 1989 through September 1992, 551 patients were randomized to start receiving a daily dietary supplement of 10 1-g gelatin capsules containing 80.6% ethyl esters of omega-3 fatty acids providing 4.1 g eicosapentaenoic acid (EPA) and 2.8 g docosahexaenoic acid (DHA) with 12 mg a-tocopherol and 28 mg y-tocopherol or an equal amount of an ethyl ester of corn oil as placebo (provided by the Biomedical Test Materials of the National Institutes of Health and produced by the National Marine Fisheries Service Laboratory). The corn oil and fish oil capsules were dispensed by the research pharmacist at each collaborating center according to a randomization schedule generated by the study statistician. At each center, only the research pharmacist was unblinded to the treatments. At the Data Coordinating Center, only the statistician and principal investigator were unblinded. To blind the patients to capsule contents, a very small amount (0.4%) of fish oil was added to the corn oil, yielding 2 and 1.2 mg/d of EPA and DHA, respectively. To check the accuracy of dispensed capsules, capsules were sent periodically from each center by the research pharmacist to the principal investigator for analysis of contents. All analyses confirmed correct assignment in accord with the randomization schedule.
All patients received instructions on following a Step-One American Heart Association diet24 for the duration of the study, and this was reinforced during monthly telephone interviews with each patient throughout the study. However 
Definition of Restenosis
The criteria for restenosis are that QCA of the angiogram by 6 months shows >30% increase in narrowing at the stenosis site or loss of at least half of the gain achieved at the time of successful PTCA and a final restenosis with <50% luminal diameter remaining. 25 
PTCA Procedure
PTCA was performed using an over-the-wire system. On the day before the procedure, patients started receiving a calcium channel blocker (60 to 90 mg diltiazem TID or 10 to 20 mg nifedipine TID) and 325 mg/d aspirin. Patients in the fasting state were pretreated with diazepam and diphenylhydramine. Heparin (10 000 U IV) was administered, followed by 5000 U IV every hour during the angioplasty. Before dilation of the coronary artery, 200 ,ug nitroglycerin was administered, and coronary cineangiograms of the obstructed vessels were obtained using standard projections similar to those used in the National Heart, Lung, and Blood Institute TIMI trial. 26 The angioplasty was complete when there was angiographic evidence of >20% reduction in stenosis with a hemodynamically insignificant residual stenosis (<50%). The Each cardiac catheterization facility was standardized for uniformity of procedure. Quantitative measurements were calibrated using the guiding catheter as the reference dimension. This allowed absolute dimensions of all vessel diameters to be quantified and compared. In addition to the standard projections, the best camera angles for visualization of stenotic areas were filmed together with paired orthogonal views, and the angles were recorded for reproducible positioning on subsequent filming. The locations in the coronary arteries of the index lesion that underwent angioplasty in this study were left anterior descending, 26%; left circumflex, 10%; right coronary, 29%; other, 10%; and multiple vessels, 26%, with no differences between the corn oil and fish oil groups.
Repeat angiography was performed during the 6 months of follow-up for recurrence of ischemic symptoms and in all patients at 
Statistical Analysis
The independence of lesions in the same patient was determined using a xX test to test the null hypothesis that among patients with two lesions, the number of patients with none, one, or two restenoses would be (l-p)2, 2p(l-p), and p2, respectively, with p being the restenosis rate-in this case, 0.41. There were 79 patients who had two index lesions in this study, and 41% of these 158 lesions had restenosis. If restenosis in the two lesions was independent, then we would expect 48% of the patients to 
Restenosis Rates
The restenosis rate among analyzable patients was 46% for corn oil recipients and 52% for fish oil recipients (P=.37). Fig 2 shows the distribution function of the minimal lumen diameter (MLD) at the site of PTCA before and immediately after PTCA and at the 6-month follow-up angiogram for the two treatment groups; the curve represents the proportion of lesions that had a MLD less than the value on the abscissa. The correlation coefficient was .17 (P<.0001) for the severity of the initial stenosis and the probability of restenosis. Fig 3 is a plot of the late loss of MLD against the early gain in lumen diameter resulting from the angioplasty procedure for all lesions in the fish and corn oil groups. Complete restenosis would have fallen on the line of identity with a slope of 1.0, and no restenosis would be depicted by a horizontal line. Although there is much scatter of the data, clearly the preponderance of results indicates some restenosis, and no difference is seen between the line of best fit for the fish oil and corn oil treatment groups.
Because of concern that the supplement of polyunsaturated fatty acids in both corn and fish oil might increase damage to cells from lipid peroxidation, all patients were started on a daily supplement of 200 mg dl-a-tocopheryl acetate (Schein Pharmaceutical, Inc) in March 1991, when one third of the final number of patients had been enrolled. The addition of this dose of vitamin E did not affect the restenosis rates. For the 134 patients who received no vitamin E supplement, equally divided between the treatment groups, stenosis rates were 44% and 51% for the corn oil and fish oil groups, throughouit the study, rates were 47% and 54% for the corn oil and fish oil groups, respectively.
There were no significant differences between the two treatment groups for any of the patient characteristics listed in Table 1 Gastrointestinal symptoms were reported in 8% of the corn oil recipients and 7% of the fish oil recipients; 3% of the corn oil recipients and 1 % of the fish oil recipients withdrew from the study because of adverse cardiovascular events. There were no other miscellaneous adverse events affecting the study, and at no time during the course of the study did significant differences in events occur between treatment groups. Laboratory Analyses Table 3 gives the values for the standard plasma lipids, Lp(a), body weight, blood pressure, pulse, hemoglobin, hematocrit, white blood cell count, platelets, and bleeding time. reduction in triglycerides by 41% in the fish oil group compared with 14% in the corn oil group and the reduction in total cholesterol in the fish oil group. Also of importance to this study is the evidence that with the fish oil supplement, EPA and DHA displaced arachidonic and linoleic acids in both plasma and red blood cell phospholipids (Fig 4A and 4B) . Data are shown at entry (baseline), at PTCA, at 3 months, and on exit from the study (generally 6 months but earlier in :30% of patients whose recurrence of angina led to an early exit from the study).
There were no significant differences between the combined urinary metabolites of the dienoic and trienoic thromboxanes in the restenosis or no-restenosis patients in either the corn oil or fish oil group (data not blood pressure; SBP, systolic blood pressure; T-Chol, total i, low-density lipoprotein cholesterol; Lp(a), lipoprotein (a); and shown). Because all patients were prescribed 325 mg/d aspirin, this is not a surprising finding. However, 41% and 48% of patients receiving corn and fish oil, respectively, had exit levels of thromboxane urinary metabolites of >50 ng/g creatinine, suggesting poor compliance with the daily aspirin prescription. When restenosis was examined as a function of aspirin compliance, however, no significant correlations were found. Urinary PGI2 metabolite levels at exit were negatively correlated, as expected, with both EPA and DHA levels in the plasma and red blood cell phospholipids (for the red blood cells, r= -.32, P=.004; and r= -.27, P=.02 for EPA and DHA, respectively). With PGI3, the correlations with plasma phospholipid levels were positive, also as expected (r=. 18 DHA, respectively). PGI2 levels at exit in either treatment group were not significantly different for restenosis and no-restenosis patients. However, with PGI, for corn oil-supplemented patients (n=29) who restenosed, the mean level of urinary metabolites was 0.17 +0.09 ng/g creatinine at exit, whereas the value for patients with no restenosis (n=48) was 1.02±0.24 ng/g creatinine (P=.002). This finding is unexplained as in the fish oil-supplemented patients who restenosed, PGI3 excretion values were 10-fold higher. Discussion
The present study was a randomized, double-blind, placebo-controlled clinical trial that included 474 evaluable patients who had undergone successful angioplasty 6 months earlier. The number of patients was calculated with the following assumptions: the expected rate of restenosis at 6 months after PTCA was 30%; a 33% reduction in the restenosis rate from our intervention would be considered a therapeutic success; a error was .05; and power was .80. The calculation indicated a need for 230 patients in the placebo group receiving corn oil containing polyunsaturated omega-6 fatty acids and in the intervention group receiving a concentrated fish oil preparation containing omega-3 polyunsaturated fatty acids. With the definition of restenosis used as the primary end point of this study, the observed restenosis rate judged by QCA was :50%, which is consistent with what has been reported when similar criteria of restenosis were used and QCA interpretation was applied to all study subjects." This higher-than-expected restenosis rate should have made it easier to detect a significant effect of the fish oil intervention on reducing the restenosis rate had such an effect existed. Furthermore, the high restenosis rate in each group indicates that the failure to detect an effect of the fish oil supplement was not due to a beneficial effect that was masked by a similar beneficial effect from the corn oil supplement. The 95% confidence interval for the decrease in the risk of restenosis with fish oil compared with corn oil was -37% to +6%. Thus, the data were consistent with, at A .X.. There are a number of differences in design other than size of the individual studies that deserve comment. The end point selected may change the total percentage of restenoses diagnosed, but because the same criteria apply to both control and intervention cohorts, it would not hide a significant difference. In addition to the definition of restenosis used in this study, one can see from Fig 3 that when all the angiographic data for each patient are plotted as "acute change" (the difference between lumen diameter at the stenotic site just before and that just after angioplasty) against the "late loss" (the difference in lumen diameter at exit and that on post-PTCA angiograms), there is no significance difference in the lines of best fit for the corn oil group versus the fish oil group.
The time before PTCA when the oil supplements were started was another variable among published studies. Since the stimulus for repair at the site of angioplasty must be at or near maximal at the time of dilation of the stenotic site, it would seem essential that any protective measure be in place at the time of angioplasty. In some reported studies, the fish oil supplement was started on the day of the angioplasty or the next day, whereas in the Quebec study,19 which showed a benefit, the oil supplement was started 3 weeks before angioplasty. We advised 14 days but compromised to make 12 days the minimal allowable interval before PTCA.
We chose to apply the very large dose of 8 g/d omega-3 fatty acids for the 6 months of the study. This supplement provided 4.1 g DHA (C22:6n-3) and 2.8 g EPA (C20: 5n-3), the two highly unsaturated fatty acids to which antiatherogenic effects of fish and fish oil have generally been ascribed. This high dose, approaching the intake of Greenland Inuits, was chosen with the hope of overcoming any antagonistic effects of other fatty acids competing with those of EPA or DHA, such as arachidonic acid or saturated fats. Although all patients were prescribed a diet with 30% energy from fat, this study was intended as a test of the effects of a supplement not requiring strict additional dietary restrictions. This dose is higher than that used in any of the earlier studies, and it was administered as the ethyl esters of the omega-3 fatty acids, which are well absorbed.31 However, a recent report indicates that a high saturated fatty acid intake can diminish the potential benefits of a given intake of omega-3 fatty acids. 32 With the high dose of supplements used, the plasma phospholipid levels of the omega-3 EPA and DHA rose promptly in association with a reciprocal decrease in omega-6 linoleic acid and arachidonic acid, so that at the time of PTCA steady-state levels were essentially achieved (Fig 4A) . Such a prompt attainment of steadystate levels, however, was not achieved in the phospholipids of the red blood cells (Fig 4B) . At The blood lipid profile showed the characteristic large decrease in triglycerides in the group receiving fish oil (41% in this trial) but no other significant differences. With fish oil, both total and LDL cholesterol decreased minimally, and HDL cholesterol rose slightly but without reaching significance between the treatment groups. A subset of 62 patients had determinations of Lp(a) levels, and no significant effect of fish oil was found on this atherogenic lipoprotein.
The effect of cigarette smoking on restenosis is unexplained. A similar effect of cigarette use was observed in the TIMI-II trial. 33 In that study, the authors showed that the cigarette smokers constituted a younger group of angioplasty patients and with that difference had fewer other risk factors for coronary heart disease to which the lower restenosis rate was attributed. A similar comparison of risk factors between the smokers and nonsmokers in our study does not appear to have a similar explanation, since we did not find any striking differences in medical history and risk factors between smokers and nonsmokers, which were found by Mueller et al. 33 Of the current smokers in our study, the proportion of male and female smokers, presence of diabetes, history of myocardial infarction or angina, previous PTCA or CABG, blood pressure level, years of coronary artery disease, angina class, and mean lumen diameter at the site of angioplasty before and after PTCA did not differ significantly. Of the smokers, 16% had multiple-vessel disease compared with 28% of nonsmokers, and 38% of the latter had right coronary artery stenosis compared with 26% of the smokers. But when classified according to the most common disease locations (left circumflex coronary, left anterior descending coronary, right coronary, and other arteries), the association with smoking was not significant (P= .22). Only for body weight was there a significant difference (P=.02), as 19% of the smokers were overweight, and 25% of the nonsmokers were overweight.
When these variables were included in a logistic regression, only age, previous PTCA, left anterior descending coronary artery as location of the lesion, multiple lesions, and pre-PTCA lumen diameter were significantly prognostic, but they were the same for smokers and nonsmokers. However, even if one corrected for all of these variables, smoking remained prognostic for favorable outcome from PTCA. Recently, a TIMI-4-related study34 also reported that smokers were found to have a better outcome with thrombolysis than nonsmokers. Recurrence of ischemia was less, and mortality rates were reduced by approximately one half. Thus, there appears to be increasing evidence that some of the invasive therapies share a paradoxical better outcome for smokers than for nonsmokers. Perhaps some toxin in cigarette smoke can inhibit the proliferation of smooth muscle cells in this condition, despite the well-documented general atherogenic effect of smoking.
Although there has been much concern regarding the possibility of excessive bleeding resulting from ingestion of fish oils, no difference in clinically significant bleeding was noted despite the invasive angioplasty procedure and the fact that all patients received 325 mg/d aspirin. All bleeding times were within the normal range, but the fish oil-supplemented subjects had a small but significant increase between the value at PTCA and that at 3 months (P<.01).
